Medication mechanisms, benefits, and tradeoffs
Compare major glucose-lowering drug classes by biological target, weight effects, hypoglycemia risk, organ evidence, and practical limitations.
By The Diabetes Guide editorial project · Updated 30 Sept 2026
On this page
Diabetes medicines work in different ways: lowering liver sugar, boosting insulin, helping the kidneys remove sugar or changing appetite.
Step 1: Different tools
Metformin lowers liver sugar. GLP-1 medicines affect insulin and appetite. SGLT2 medicines make the kidneys pass sugar out.
For example: A toolbox with many tools for different jobs.
Step 2: Weight and low sugar
Some help weight loss; others can cause weight gain or low sugar, especially with insulin.
For example: Some shoes are good for running, others for hiking; both have trade-offs.
Step 3: More than sugar
Some medicines protect heart or kidneys. That can be reason enough to use them.
For example: A raincoat that is also a warm jacket.
Remember: Choose with a clinician; table facts are not a prescription.
The full story
Want more? Below is the detailed version with the real science words. It is fine to skip it.
A mechanism map, not a prescription
Drug selection depends on the person, kidney function, cardiovascular disease, weight priorities, pregnancy considerations, adverse effects, affordability and availability. Benefits are often agent- and population-specific rather than universal across a class. 1
| Class | Mechanism | Weight / hypoglycemia | Important tradeoffs |
|---|---|---|---|
| Metformin | Mainly lowers liver glucose output | Neutral or modest loss; low hypoglycemia risk alone | Gastrointestinal effects, B12 deficiency; renal and illness context matter |
| GLP-1 receptor agonists | Increase glucose-dependent insulin, reduce glucagon, affect appetite and emptying | Often loss; low risk alone | GI effects; contraindications and tolerability vary; selected agents have CV/kidney outcome evidence |
| Dual GIP/GLP-1 agonist | Combines incretin-receptor actions | Often substantial loss; low risk alone | GI effects, cost and access; do not infer every outcome from weight loss |
| SGLT2 inhibitors | Reduce kidney glucose reabsorption | Modest loss; low risk alone | Genital infections, volume depletion, ketoacidosis risk; strong heart-failure/kidney evidence for selected agents |
| DPP-4 inhibitors | Prolong endogenous incretin action | Usually neutral; low risk alone | Modest efficacy; heart-failure cautions differ by drug |
| Sulfonylureas | Stimulate insulin secretion | Gain possible; hypoglycemia risk | Often affordable; secretion is less glucose-dependent |
| Thiazolidinediones | Improve insulin sensitivity through gene regulation | Gain possible; low risk alone | Edema, heart-failure and fracture concerns |
| Insulin | Replaces or supplements insulin supply | Gain possible; hypoglycemia risk | Very effective and essential in T1D; training, monitoring and cost matter |
| Alpha-glucosidase inhibitors | Slow intestinal carbohydrate digestion | Usually neutral; low risk alone | Gas and GI effects; meal-related use |
| Meglitinides | Shorter-acting stimulation of secretion | Gain and hypoglycemia possible | Meal-time treatment burden |
What “low risk alone” means
Combination with insulin or a secretagogue can change hypoglycemia risk. Kidney disease, poor intake and illness also change safety. A class-level table cannot replace the current product label.
Glucose improvement and organ protection
Certain therapies reduce cardiovascular or kidney outcomes in defined trials. These benefits can justify treatment even when HbA1c is near goal. Access and cost vary widely by country, insurance and formulation; no universal price ranking is reliable. 12
Trace the evidence
Sources and further reading
1.Pharmacologic Approaches to Glycemic Treatment: Standards of Care 2026 (opens in a new tab)
American Diabetes Association · 2026 · Guideline
Who was studied, limits and source check
Limitations: Recommendations require shared clinical decisions; benefits and contraindications vary by drug.
Source checked 2026-09-30. See the original publication for full methods.
2.Obesity and Weight Management: Standards of Care 2026 (opens in a new tab)
American Diabetes Association · 2026 · Guideline
Who was studied, limits and source check
Limitations: Treatment must consider nutrition, contraindications, access, and maintenance.
Source checked 2026-09-30. See the original publication for full methods.
Source checking is an editorial literature check, not independent medical review. This page is for learning. It cannot diagnose you or make a treatment plan. Evidence labels describe the cited claims, not the whole topic.
What does “Established” mean?
Doctors and scientists agree. This is well known. Like “the sun rises in the east”.
Keep reading
The body
The one-page mental model
Diabetes means there is too much sugar in the blood for too long, because the body does not have enough insulin or cannot use it well.
Type 1
Type 1 diabetes: the complete journey
Type 1 diabetes is usually an autoimmune condition. The body’s defence system harms the beta cells, so less and less insulin is made.
Type 2
Type 2 diabetes: how the system changes
Type 2 diabetes happens when the body’s need for insulin grows and the pancreas cannot keep up, so sugar slowly rises.